QIAGEN Aktie
39,42USD | -0,17USD | -0,43% |
WKN: 901626 / ISIN: NL0012169213
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,58 |
Massachusetts Financial Services Co. | 9,29 |
Massachusetts Financial Services Co. | 8,97 |
Schroder Investment Management Ltd. (13F Subfiler) | 2,91 |
Norges Bank Investment Management | 2,84 |
Government Pension Fund - Global (The) | 2,78 |
PSquared Asset Management AG | 2,72 |
Vanguard Group, Inc. (Subfiler) | 2,69 |
Norges Bank (13F) | 2,52 |
UBS Asset Management (Americas), Inc. | 2,05 |
Amundi Asset Management | 1,97 |
Pendal Group Ltd. | 1,89 |
MFS Research International Fund | 1,66 |
DZ BANK AG Deutsche Zentral-Genossenschaftsbank | 1,58 |
MFS International Growth Fund | 1,53 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 4 952 | 5 096 | 5 610 | 6 028 | 6 178 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,30 | 0,30 | 0,33 | 0,37 | 0,35 |
Bilanz (in Mio. EUR) - Aktiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 2 155 | 1 570 | 1 667 | 2 110 | 2 394 |
Summe Anlagevermögen | 4 809 | 4 301 | 4 830 | 5 137 | 5 422 |
Summe Aktiva | 5 748 | 5 236 | 5 913 | 6 147 | 6 288 |
Bilanz (in Mio. EUR) - Passiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 2 174 | 1 765 | 2 032 | 2 040 | 1 955 |
Summe Fremdkapital | 3 113 | 2 699 | 3 115 | 3 050 | 2 821 |
Summe Eigenkapital | 2 635 | 2 537 | 2 798 | 3 097 | 3 467 |
Summe Passiva | 5 748 | 5 236 | 5 913 | 6 147 | 6 288 |
Adresse
Hulsterweg 82, 5912 PL Venlo | |
Telefon | +31 (77) 355-66-00 |
Fax | +31 (77) 355-66-58 |
Internet | http://www.qiagen.com |
Management
Antonio Santos
Senior Vice President & Head-Global Operations |
Elaine R. Mardis
Independent Member-Supervisory Board |
Elizabeth E. Tallett
Member-Supervisory Board |
Eva Pisa
Member-Supervisory Board |
Jean-Pascal Viola
Head-Corporate Business Development |
John Gilardi
Vice President & Head-Investor Relations |
Jonathan G. Sheldon
Senior VP-Digital Insights Business Area |
Lawrence A. Rosen
Chairman-Supervisory Board |
Lezette Young
Manager-Compliance & Legal |
Metin Colpan
Independent Member-Supervisory Board |
Nedal Safwat
VP & Head-Molecular Diagnostics North America |
Philipp von Hugo
VP, Head-Global Legal Affairs & Compliance |
Roland Sackers
Chief Financial Officer & Managing Director |
Ross L. Levine
Independent Member-Supervisory Board |
Stephany Foster
Chief Human Resources Officer & Senior VP |
Stephen H. Rusckowski
Member-Supervisory Board |
Thierry Bernard
Chief Executive Officer & Managing Director |
Thomas Ebeling
Member-Supervisory Board |
Thomas Neidert
Vice President-Global Treasury |
Thomas Schweins
Senior Vice President-Life Science Business Area |
Thomas Theuringer
Senior Director & Head-External Communications |
Toralf Haag
Member-Supervisory Board |
Ulrich Schriek
Senior Advisor |